probenecid has been researched along with Cytomegalovirus Infections in 4 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)." | 5.08 | (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. ( Cundy, K; Drew, WL; Fisher, PE; Flaherty, J; Glutzer, E; Hannigan, J; James, C; Lalezari, JP; Martin, JC; Miner, D, 1995) |
| "0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2." | 1.29 | Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ( Cundy, KC; Fisher, PE; Flaherty, J; Hitchcock, MJ; Jaffe, HS; Lalezari, JP; Lietman, PS; Petty, BG; Polis, MA; Wachsman, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cundy, KC | 1 |
| Petty, BG | 1 |
| Flaherty, J | 2 |
| Fisher, PE | 2 |
| Polis, MA | 1 |
| Wachsman, M | 1 |
| Lietman, PS | 1 |
| Lalezari, JP | 2 |
| Hitchcock, MJ | 1 |
| Jaffe, HS | 1 |
| Drew, WL | 1 |
| Glutzer, E | 1 |
| James, C | 1 |
| Miner, D | 1 |
| Cundy, K | 1 |
| Hannigan, J | 1 |
| Martin, JC | 1 |
| Scott, RA | 1 |
| Pavesio, C | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
1 trial available for probenecid and Cytomegalovirus Infections
| Article | Year |
|---|---|
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Creatine; Cytomegalovirus | 1995 |
3 other studies available for probenecid and Cytomegalovirus Infections
| Article | Year |
|---|---|
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1995 |
Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 2000 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |